<DOC>
	<DOC>NCT01911741</DOC>
	<brief_summary>A study to evaluate the bioavailability (BA) of a single oral dose of MDV3100 (enzalutamide) formulated as a solid spray dried tablet compared to oral liquid-filled capsules, and the safety and tolerability of oral formulations. Subjects are admitted to the clinic from days 1 to 5, followed by outpatient assessments up to Day 50. They return to the clinic for an end of study visit (ESV) 7-10 days after the last pharmacokinetic (PK) sampling or after early withdrawal.</brief_summary>
	<brief_title>A Study to Compare Capsule and Tablet Forms of MDV3100 (Enzalutamide) After Administration of a Single Set Dose Under Fasted Conditions in Healthy Male Subjects</brief_title>
	<detailed_description />
	<criteria>The subject has a body mass index (BMI) range of 18.5 29.9 kg/m2, inclusive. The subject weighs at least 50 kg (screening). Male subject and his female spouse/partner who is of childbearing potential must be using highly effective contraception consisting of two forms of birth control (one of which must be a barrier method) starting at screening and continue throughout the study period and for 3 months after final study drug administration. Male subject must not donate sperm starting at screening and throughout the study period and for at least 3 months after final study drug administration. Known or suspected hypersensitivity to enzalutamide, or any components of the formulation used. Confirmed CYP2C8 poor metabolizer status based on genotyping analysis. Any history of seizure including a febrile seizure in childhood, loss of consciousness, transient ischemic attack, or any condition that may predispose to seizure. The subject has/had febrile illness or symptomatic, viral, bacterial (including upper respiratory infection), or fungal (noncutaneous) infection within 1 week prior to first clinic check in. Use of grapefruit or marmalade in the week prior to admission to the Clinical Unit, as reported by the subject. Any significant blood loss, donated one unit (450 mL) of blood or more, or received a transfusion of any blood or blood products within 60 days or donated plasma within 7 days prior to clinic admission on Day 1.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Enzalutamide</keyword>
	<keyword>Relative bioavailability of MDV3100</keyword>
	<keyword>Immediate release oral formulation</keyword>
	<keyword>Xtandi</keyword>
</DOC>